| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Sep'17 | Jun'17 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
- | 0 | 404 | 25 | 94 | 194 | 198 | 126 | 206 | - | - |
Costs and expenses: | ||||||||||
Cost of revenue | ||||||||||
- | 0 | 8 | 16 | 175 | 301 | 246 | 246 | 240 | - | - |
Research and development | ||||||||||
5,409 | 4,411 | 6,543 | 7,304 | 7,412 | 7,073 | 5,314 | 5,512 | 4,454 | 4,292 | 3,392 |
General and administrative | ||||||||||
1,750 | 1,928 | 1,531 | 1,563 | 1,647 | 1,381 | 1,092 | 925 | 1,221 | 1,040 | 1,274 |
Total costs and expenses | ||||||||||
7,159 | 6,339 | 8,082 | 8,883 | 9,234 | 8,755 | 6,652 | 6,683 | 5,915 | 5,332 | 4,666 |
Loss from operations | ||||||||||
-7,159 | -6,339 | -7,678 | -8,858 | -9,140 | -8,561 | -6,454 | -6,557 | -5,709 | -5,332 | -4,666 |
Change in fair value of derivative liabilities | ||||||||||
- | - | - | - | - | 0 | 31 | 30 | 308 | 157 | 149 |
Interest expense | ||||||||||
- | - | - | - | - | 0 | 44 | 81 | 267 | 361 | 355 |
Loss on extinguishment of related party convertible promissory note | ||||||||||
- | - | - | - | - | 0 | -199 | 0 | -2,180 | - | - |
Other income (expense), net | ||||||||||
10 | 13 | 36 | 30 | 73 | 112 | 67 | 0 | -14 | - | -7 |
Loss before provision for income taxes | ||||||||||
-7,149 | -6,326 | -7,642 | -8,828 | -9,067 | -8,449 | -6,599 | -6,608 | -7,862 | -5,536 | -4,879 |
Provision for income taxes | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
Net loss | ||||||||||
-7,149 | -6,326 | -7,642 | -8,828 | -9,067 | -8,449 | -6,599 | -6,608 | -7,862 | -5,536 | -4,879 |
Net loss attributable to noncontrolling interests | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
Net loss attributable to Vaccinex, Inc. common stockholders | ||||||||||
-7,149 | -6,326 | -7,642 | -8,828 | -9,067 | - | -6,599 | -6,608 | - | -5,536 | -4,879 |
Comprehensive loss | ||||||||||
-7,149 | - | - | - | -9,067 | - | - | - | - | - | - |
Cumulative dividends on redeemable preferred stock | ||||||||||
- | - | - | - | - | - | - | -800 | - | -809 | -800 |
Net loss attributable to Vaccinex, Inc. common stockholders, basic and diluted | ||||||||||
- | - | -7,642 | -8,828 | - | - | -6,599 | -7,408 | -7,862 | -6,345 | -5,679 |
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted | ||||||||||
-0.45 | -0.35 | -0.56 | -0.77 | -0.79 | 9.13 | -0.93 | -6.72 | -7.13 | -5.75 | -5.15 |
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted | ||||||||||
16,001 | 14,808 | 13,759 | 11,479 | 11,475 | 11,610 | 7,078 | 1,103 | 1,102 | 1,102 | 1,101 |